[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339436-105":59,"doc-detail-339436-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pathway-based-signatures-predict-patient-outcome-chemotherapy-benefit-and-synthetic-lethal-dependencies-in-invasive-lobular-breast-cancer","Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer","","Invasive lobular carcinoma (ILC) is a distinct breast cancer subtype with poorer long-term outcomes and characteristic metastasis patterns, yet robust prognostic biomarkers and actionable molecular pathways remain limited. This study develops pathway-centric multivariable machine-learning models and validates them across seven retrospective clinico-genomic cohorts and an independent RNA-Seq clinical cohort. Dysregulation scores of 25 pathways predict outcome, with three pathways also indicating chemotherapy response. A PSILC predictor is built and validated for overall and metastasis-free survival. Integration with CRISPR-Cas9 screening identifies 16 synthetic-lethal therapeutic targets, providing interpretable biomarkers to support targeted drug discovery.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pathway-based-signatures-predict-patient-outcome-chemotherapy-benefit-and-synthetic-lethal-dependencies-in-invasive-lobular-breast-cancer/339436/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pathway-based-signatures-predict-patient-outcome-chemotherapy-benefit-and-synthetic-lethal-dependencies-in-invasive-lobular-breast-cancer/339436.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on invasive lobular breast cancer?","Question",{"text":112,"@type":113},"To develop interpretable, pathway-based biomarkers that predict patient outcome and chemotherapy benefit in ILC, and to identify molecular targets for targeted therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the predictive models validated?",{"text":117,"@type":113},"The pathway-centric machine-learning models were trained and tested in seven retrospective clinico-genomic cohorts, then externally validated using a new RNA-Seq clinical cohort of aggressive ILC.",{"name":119,"@type":110,"acceptedAnswer":120},"Which pathways were linked to both prognosis and chemotherapy response?",{"text":121,"@type":113},"Cell-cell communication, innate immune system, and smooth muscle contraction pathways were independent predictors of chemotherapy response and also showed prognostic value in ILC.",{"name":123,"@type":110,"acceptedAnswer":124},"What additional discovery was made by integrating PSILC with CRISPR screening data?",{"text":125,"@type":113},"The integration revealed 16 candidate therapeutic targets that are synthetic lethal with high-risk ILC.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},339436,1790324186,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN  \nGenetics and Genomics  \nPathway-based signatures predict patient outcome, chemotherapy beneﬁt and synthetic lethal dependencies in invasive lobular breast cancer  \nJohn Alexander 1, Koen Schipper 1, Sarah Nash1,2, Rachel Brough1,3, Harriet Kemp1, Jacopo Iacovacci1, Clare Isacke 1, Rachael Natrajan 1, Elinor Sawyer 2, Christopher J. Lord 1,3 and Syed Haider 1 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | BACKGROUND: Invasive Lobular Carcinoma (ILC) is a morphologically distinct breast cancer subtype that represents up to 15% of all breast cancers. Compared to Invasive Breast Carcinoma of No Special Type (IBC-NST), ILCs exhibit poorer long-term outcome anda unique pattern of metastasis. Despite these differences, the systematic discovery of robust prognostic biomarkers and therapeutically actionable molecular pathways in ILC remains limited.\u003Cbr>METHODS: Pathway-centric multivariable models using statistical machine learning were developed and tested in seven retrospective clinico-genomic cohorts (n = 996) . Further external validation was performed using a new RNA-Seq clinical cohort of aggressive ILCs (n = 48) .\u003Cbr>RESULTS AND CONCLUSIONS: mRNA dysregulation scores of 25 pathways were strongly prognostic in ILC (FDR-adjusted P \u003C 0.05) . Of these, three pathways including Cell-cell communication, Innate immune system and Smooth muscle contraction were also independent predictors of chemotherapy response. To aggregate these ﬁndings, a multivariable machine learning predictor called PSILC was developed and successfully validated for predicting overall and metastasis-free survival in ILC. Integration of PSILC with CRISPR-Cas9 screening data from breast cancer cell lines revealed 16 candidate therapeutic targets that were synthetic lethal with high-risk ILCs This study provides interpretable prognostic and predictive biomarkers of ILC which could serve as the starting points |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>for targeted drug discovery for this disease. |  |  |\n|  | British Journal of Cancer (2024) 130:1828–1840; [https://doi.org/10.1038/s41416-024-02679-7](https://doi.org/10.1038/s41416-024-02679-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nInvasive Lobular Carcinoma (ILC) is the second most frequently occurring histological subtype of breast cancer after Invasive Breast Carcinoma of No Special Type (IBC-NST, formerly referred to as invasive ductal carcinoma or IDC), representing up to 15% of all breast cancer cases (reviewed in [1–3]) . ILC is commonly distinguished by small discohesive cancer cells permeating the stroma in an individually dispersed or single-ﬁle pattern [1, 2, 4]. The loss of the calcium-dependent cell-cell adhesion protein, E-cadherin (encoded by CDH1) is thought to cause the lack of cellular cohesion in ILCs and is seen in over 85% of ILCs [1, 5] . In addition to E-cadherin deﬁciency, ILCs exhibit a low proliferation index (Ki67), oestrogen receptor (ER) and progesterone receptor (PgR) positivity, and low tumour purity [2, 5] . Compared to ER positive (ER+) IBCNST, ER+ ILCs present distinctive morphological and pathologic features with worse disease free and overall survival at 10 years, and unusual metastatic patterns [2, 6–8] .  \nLarge-scale genomic studies have revealed a higher alteration rate in driver genes PIK3CA, TBX3, FOXA1, RUNX1 and PTEN, and a lower alteration rate in TP53, MYC, ERBB2/3 and GATA3 [5, 9, 10] in  \nILCs when compared to IBC-NST. Mutations in PIK3CA and AKT1 along with PTEN inactivating events in ILCs lead to increased activity of the PI3K/Akt signalling pathway [5] . Pathways including MAPK and metabotropic glutamate receptor signalling [5], WNT4 signalling [11] and ERRγ/AP1 signalling [12] have also been linked to therapy resistance, suggesting ILCs ","cbCaiqasY7rP9JOT","https://ap.wps.com/l/cbCaiqasY7rP9JOT","pdf",1202031,13,"English","# Background\n# Methods\n# Results and conclusions\n# Introduction","[{\"question\":\"What is the main goal of this study on invasive lobular breast cancer?\",\"answer\":\"To develop interpretable, pathway-based biomarkers that predict patient outcome and chemotherapy benefit in ILC, and to identify molecular targets for targeted therapies.\"},{\"question\":\"How were the predictive models validated?\",\"answer\":\"The pathway-centric machine-learning models were trained and tested in seven retrospective clinico-genomic cohorts, then externally validated using a new RNA-Seq clinical cohort of aggressive ILC.\"},{\"question\":\"Which pathways were linked to both prognosis and chemotherapy response?\",\"answer\":\"Cell-cell communication, innate immune system, and smooth muscle contraction pathways were independent predictors of chemotherapy response and also showed prognostic value in ILC.\"},{\"question\":\"What additional discovery was made by integrating PSILC with CRISPR screening data?\",\"answer\":\"The integration revealed 16 candidate therapeutic targets that are synthetic lethal with high-risk ILC.\"}]","Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer | PDF",1790030290,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3da025f9648b411c11bc00a85e52977c.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5936ff365f811b1e567fac8efb75615.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0b681c09fdca5de0130b02dd79a6c3d.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/addd35d51b9b726f038e2ecf286cd0fa.webp",980,1301]